Design of a synthesis-friendly hypoxia-responsive promoter for cell-based therapeutics

Chee Ka Candice Lam 1 | Kevin Truong 1,2

  1 Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada
  2 Edward S. Rogers Sr. Department of Electrical and Computer Engineering, University of Toronto, Toronto, ON, Canada

Correspondence
Kevin Truong, Institute of Biomedical Engineering, University of Toronto, 164 College Street Room 407, Rosebrugh Building, Toronto, ON M5S3G9, Canada.
Email: kevin.truong@utoronto.ca

Funding information
Canadian Institutes of Health Research, Grant/Award Number: PJT-156317; Natural Science and Engineering Research Council NSERC, Grant/Award Number: RGPIN-2019-04183

Abstract
Towards the goal of making ‘smart’ cell therapies, one that recognizes disease conditions (e.g. hypoxia) and then produces mitigating biologics, it is important to develop suitable promoters. Currently, hypoxia responsive promoters are composed of strongly repeated sequences containing hypoxia response elements upstream of a minimal core promoter. Unfortunately, such repeated sequences have inherent genomic instability that may compromise the long-term consistency of cell-based therapeutics. Thus, we designed a synthesis-friendly hypoxia-inducible promoter (named SFHp) that has GC content between 25% and 75% and no repeats greater than 9 base pairs. In HEK293 cells stably integrated with genes regulated by synthetic SFHp, we demonstrated inducible reporter expression with fluorescent proteins, cell morphology rewiring with our previously engineered RhoA protein and intercellular cell signalling with secreted cytokines. These experiments exemplify the potential usage of SFHp in cell-based therapeutics with integrated genetic circuits that inducibly respond to the disease microenvironment.

KEYWORDS
biosensor, hypoxia, inducible expression, promoter design, synthetic promoters

1 | INTRODUCTION

Cell-based therapeutics use genetically engineered cells as vehicles of delivery for biologics in the treatment or prevention of diseases [1, 2]. In these therapies, the stable integration of transgenes, most commonly through lentiviral or retroviral methods, is critical for consistent clinical responses in patients [3]. While constitutive gene expression is most common, the creation of a ‘smart’ cell-based therapy requires the cell sense disease conditions and then subsequently secrete the mitigating therapeutic protein. Such inducible expression is especially important due to their ability to reduce side-effects within the cell such as death, delayed growth, compensatory adaptations and off-target effects throughout the body [4]. Variations in spatial and temporal phenotype can be accomplished with regulated promoters that reversibly fine-tune levels of expression in response to different environmental conditions based on the activation and inactivation of transcription factors. For example, studies demonstrate...
naturally occurring inducible systems activated by different environmental stressors such as hypoxia, temperature, nutrient-availability and mechanical-stimuli as mechanisms of controlling mammalian gene expression [5–8]. In clinical settings, hypoxia-induced gene regulation is particularly important to harness due to the wide-spread presence of hypoxia in disease microenvironments [9].

Promoters regulate transcription initiation at the correct transcriptional start site (TSS) and control expression levels depending on the conditions of the cell. Both of these are achieved through the use of conserved sequence elements located upstream of transgenes. The minimal core promoter is responsible for specifying the TSS to transcription machinery [10]. It often contains the evolutionarily conserved TATA box, TATAWAWR and mammalian initiator sequence, YYANWYY, which encompasses the TSS [10, 11]. Alone, the core promoter has very low basal expression levels. Higher levels of expression require enhancer sequences that bind activating transcription factors adjacent to the promoter and in turn recruit transcription machinery [12]. Accordingly, inducible expression of genes is established by conditional binding of transcription factors to distal and/or proximal enhancer regions upon specific environmental stimuli, drastically increasing the relative transcription levels compared to the non-induced minimal promoter alone. For hypoxia-induced response in cells, this process is mediated by signalling pathways that control hypoxia-inducible transcription factor (HIF)-alpha subunit and HIF-beta that dimerize and bind to hypoxia response elements (HREs) when localized to the nucleus [13, 14].

Targeting the hypoxic microenvironment with cell-based therapeutics is particularly promising because of its role in a number of different diseases, including heart disease, cancer and rheumatoid arthritis [15, 16]. While it is possible to use endogenous promoters (e.g. the VEGF or EPO promoter) that have HRE sites, these promoters contain other response elements that may be inducible by other pathways [17, 18]. To avoid these cross pathway effects, it is possible to design custom promoters with only HRE sites. Since each transcription factor binding site functions as an independent unit, they can be combined in different manners to vary promoter expression levels as long as the minimal core promoter remains intact [19]. For example, the commonly used commercial hypoxia-responsive promoters were designed to include several repeats of HRE (i.e. the conserved binding site for HIF dimers) placed upstream of a minimal core promoter [20–22]. Unfortunately, the sequence repeats in these promoters are considered complex for gene synthesis because of the interference of repeating sequences during Gibson assembly [23]. More concerning, these exact sequence repeats make the genetic material unstable due to a greater potential for replication slippage, misalignment and homologous recombination [24]. As a result of genomic instability arising from repeats, our group and others have designed promoter sequences to be less repetitive [25, 26]. Outside of repeats, high GC content (e.g. 80% is considered very high) is also undesired for gene synthesis because PCR itself becomes inefficient [27]. Thus, to enable both cost effective de novo synthesis and genomic stability, we have created a synthesis-friendly alternative, named synthesis-friendly hypoxia-inducible promoter (SFHp), with no extreme GC content or repeats greater than 9 base pairs. To demonstrate the functionality of SFHp, we used an established chemical-based model to activate the HIF signalling pathway [28–30]. These experiments showed our promoter can be induced to express proteins for fluorescence imaging, protein switches for pathway rewiring and cytokines for intercellular signalling. In particular, the use of SFHp to produce a cytokine or signalling molecule allows communication and coordination with other engineered cell lines or host cells for developing more versatile cell-based therapies.

2 | MATERIALS AND METHODS

2.1 | Promoter design

HRE with the consensus sequence 5′ TACGTG 3′ was used to design the enhancer region of SFHp. The exact repeat including the HRE (i.e. 5′ GTGACTACGTGCATGCTAG 3′) from plasmid pGL4.42 was concatenated seven times to form the seed sequence for optimization. This seed sequence was optimized using the dnachisel python package with constraints that enforce no repeats greater than 9 bp, GC content between 25% and 75% and seven occurrences of the HRE (i.e. 5′ TACGTG 3′). Upon program execution, dnachisel randomizes the seed sequence until all constraints are satisfied. The final optimized seed sequence was then concatenated with the minimal CMV core promoter to create SFHp. Sequence repeats were
identified using the EMBoss dottup online tool with a window size of 10 bp, plotting each sequence against itself. GC-content plots were generated in RStudio using packages 'seqinr' and 'ggplot2' with a window size of 30 bp.

2.2 Plasmid construction

All synthesis and subcloning of plasmids was done by GenScript. The SFHp sequence is CGTGAATACGTGCCGTAGAGGACTCACACGTGAGACGGTGACGTCGCCGACCTAGACGGCTACGTGCTGCCTAGACTACCCGCACGTAGGCGGACGTGATCCACGTAGGCGGACGTGACGTACGTGCTGCCTAGACTACCCGCACGTACGGAGACGTCACTACGTGTACCTATCGCGGTAGGCGTGTACGGTGGGAGGTCTATATAATGGAAGCTCGACTTCCAGCTTGGCAATCCGGTACTGCTGTCCCAATCCCGTTGGTAAAGCCGCCATG. The HRE promoter from plasmid pGL4.42 is CGTGACTACGTGCTGCCTAGCGTGACTACGTGCTGCCTAGCGTGACTACGTGCTGCCTAGCGCGGAGACACTAGAGGGTATATAATGGAAGCTCGACTTCCAGCTTGGCAATCCGGTACTGCTGTCCCAATCCCGTTGGTAAAGCCGCCATG. Active tumour necrosis factor alpha (TNFα) was assembled as the tandem fusion of the IL4 leader sequence (1MGLTSQLPLFFLACATCFVHG24) and a fragment resulting from TACE cleavage of TNFα (amino acids 77–233). Similarly, the Ceru, CaRQ, Venus and active TNFα sequences were human codon-optimized inserted into the SFHp plasmids by GenScript (Table S1).

2.3 Stable cell culture creation

Cells were maintained in Dulbecco's modified Eagle's medium containing 25 mM D-glucose, 1 mM sodium pyruvate and 4 mM L-glutamine (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA) in T25 flasks and incubated at 37°C and 5% CO2. The above designed plasmids were used to create stable HEK293 cells by lentiviral infection as previously described [31]. Specifically, HEK293 cells at 90% confluence were infected with lentivirus containing genetic cargo of interest for 24 h. The growth media was changed the next day and the cells were grown for 1 week to allow sufficient time for genomic integration. Then, the cells are serially diluted into 96-wells with 1 μg/mL of puromycin resistance for selection. After 2 weeks, colonies derived from single cells were isolated from individual wells of the 96-well plate. Individual colonies were screened for inducibility after a 24 h stimulation with 1 mM dimethylxalylglycin (DMOG) (Cedarlane).

2.4 Imaging

Prior to imaging, cells were plated in 96-well glass-bottom plates (Mattek). Images were taken with the Olympus IX81 microscope, using a Lambda DG4 xenon lamp for the light source, and a QuantEM 512SC CCD camera with a 10x objective or 40x objective (Olympus). Excitation (EX) and emission (EM) filter bandpass specifications were as follows, for fluorescent proteins: Ceru (EX: 438/24, EM: 482/32) and Venus (EX: 500/24, EM: 524/27) (Semrock). Images were analysed via ImageJ and μManager software. Time-lapse images were taken 10 s apart with 1 s exposure. Imaging was conducted with cells washed and maintained in PBS with CaCl2 (Sigma). Blebbing was induced in HEK293 cells expressing CaRQ with stimulation of 10 μM ATP (Sigma).

3 RESULTS AND DISCUSSION

3.1 Design of a SFHp

An SFHp was created by staggering the placement of seven HRE (i.e. 5′ TACGTG 3′) that have no repeats in the flanking subsequences upstream of a minimal CMV core promoter [32]. The HRE sites allow hypoxia dependent binding by HIF dimers and subsequent gene expression while the core promoter allows accurate initiation at the TSS. Using self dot plots to identify repeated sequences (i.e. diagonal lines on the dot plot), we detected that the commonly used commercial HRE promoter from plasmid pGL4.42 (Promega) has strongly repeated segments arising from the four HRE and flanking subsequences that are exactly the same (Figure 1B, top). In contrast, our SFHp lacks any strongly repeated segments by eliminating all repeats greater than 9 base pairs in the forward or reverse direction (Figure 1B, bottom). This was accomplished by varying spacing and randomizing bases flanking the HRE sites. Our final design of SFHp contained seven HRE sequences compared to the four HRE sequences found in pGL4.42 (Figure 1A). Previous studies with HRE-based promoters have shown that hypoxia inducibility is dramatically increased with only two HRE sites but there is further inducibility with more HRE sites although less and less improvement was observed [33]. As we altered the flanking subsequences, we also maintained the GC content of each 30 bp window of the promoter within the synthesis friendly range of 25–75% (Figure 1C).
3.2 | SFHp can be induced to express fluorescent protein

To show that SFHp has inducible gene expression, we created stable HEK293 cells by lentiviral infection that expressed cyan fluorescent protein Cerulean (hereafter, Ceru) all under regulation of SFHp (Figure 2A). HEK293 cell line was chosen for all our tests because it easily uptakes genetic material [34] and has also been frequently used to test hypoxia inducible promoters. Previously, HEK293 cells have been used in hypoxia specific gene therapy studies for diseases such as breast cancer tumours, ischemic myocardium and sleep apnoea [35–37]. For reproducible and robust results, we used lentiviral infections to create stable integrations of the above construct into HEK293 cells and subsequent serial dilution to select cells growing from a single progenitor cell to ensure consistent cell-wide Ceru expression upon hypoxic conditions (Figure 2C–E). Ceru expression was stimulated by the addition of 1 mM DMOG into the cell culture media. This is an established model used to express genes that respond to hypoxia through induction of HIF-1α signal pathway, despite normoxic cell culture environment [28–30]. From the media, DMOG readily permeates the extracellular membrane and is converted by de-esterization to N-oxylglycine (NOG) in the cytosol. NOG functions as a competitive inhibitor of prolyl hydroxylase domain proteins and blocks their ability to attach hydroxylations on HIF-1α transcription factors. These modifications occur during normoxic conditions to label HIF-1α for proteasome degradation. In the absence of hydroxylation, cytoplasmic HIF-1α concentration is stabilized and translocated across the nuclear envelope where HIF-1α dimerizes with HIF-1β to bind and activate gene
transcription from promoters containing HRE sites [38]. Thus, addition of DMOG results in hypoxic gene expression profiles expected for HRE promoters like our synthetic SFHp. To test that SFHp behaved similarly to the commercial HRE promoter in pGL4.42, transient transfection experiments were performed in HEK293 cells upon induction with DMOG (Figure S2). Unfortunately, the generation of stable cells using the commercial HRE promoter in pGL4.42 was challenging, possibly due to the presence of the exact repeats causing slippage. Next, we imaged the SFHp stable cells at 10× and 40× magnification, 24 h after 1 mM DMOG addition and clearly observed expression of Ceru fluorescent protein in every HEK293 cell (Figure 2D,E). The absence of fluorescence before DMOG stimulation indicates that our synthetic SFHp promoter is inducible in response to HIF-1α activity (Figure 2C). Furthermore, by nature of our single progenitor cell selection process following integration, the activity of our inducible SFHp promoter was reversible upon removability of DMOG from the media.

3.3 SFHp can express functional membrane-localized engineered RhoA

To show that SFHp can inducibly express proteins that can alter the intracellular functions, we created stable HEK293 cells by lentiviral infection that expressed an engineered Ca^{2+} activated RhoA protein (named CaRQ) under SFHp (Figure 3A). Our group previously engineered CaRQ as a chimeric RhoA GTPase that requires binding to Ca^{2+} in order to fold into the active structure for cytoskeletal remodelling (e.g. blebbing) ultimately resulting in directed cell migration (Figure 3D). The Ca^{2+} sensitivity of CaRQ allows cell migration to be rewired to any external stimulus that produces a cytosolic Ca^{2+} signal [39]. To direct plasma membrane localization, CaRQ is fused to the Lyn sequence MGCIKSKGDSA (called pM Lyn) at the N-terminus; to visualize expression, it is fused to the yellow fluorescent protein Venus [40]. Likewise, for reproducible and robust results, we used lentiviral infections to create stable integrations of the above construct into HEK293 cells and sub-
sequent serial dilution to select cells arising from a single progenitor. As expected, there was Venus fluorescence at the plasma membrane of these cells following addition of DMOG stimulus (Figure 3B, C). Since \textsuperscript{PM}Lyn requires Met1 to be cleaved for lipid modifications that anchor tagged the protein to the plasma membrane, the apparent membrane localization of CaRQ means transcription occurred at the SFH promoter rather than by read-through expression \cite{41}. Next, a bolus addition of 10 \(\mu\)M ATP was used to trigger Ca\textsuperscript{2+} efflux from endoplasmic reticulum, thereby raising cytosolic Ca\textsuperscript{2+} concentrations \cite{39}. After a couple minutes, we observed the formation and retraction of blebs and projections at the cell plasma membrane indicating activation of CaRQ migratory activity (Figure 3E) (Video S1). Since the expression under SFHp retained functionality of the engineered protein CaRQ, a ‘smart’ cell-based therapy could potentially be engineered with SFHp such that it recognizes a hypoxia environment and expresses a multi-component gene circuit that rewires cell migration to seek local pathogens. This would allow the engineering of multiple conditions to be satisfied before any therapeutic intervention, providing greater specificity and reduce toxicity. For instance, hypoxia is common in the microenvironment of the tissue surrounding a bacterial infection \cite{42}. A CaRQ-based migration circuit and lysozyme could be regulated by SFHp to seek lipopolysaccharides secreted by bacteria to administer lysozyme locally. If the seeking circuit was regulated under a constitutive promoter instead, it might unintentionally treat ‘good’ bacteria in the gut.

3.4 SFHp can express functional TNF\(\alpha\) for intercellular signalling

To show that SFHp can inducibly express paracrine signals for the intercellular signalling, we created stable HEK293 cells (called ‘sender’ cells) by lentiviral infection that expressed Venus and active TNF\(\alpha\) signalling protein joined in tandem by a T2A co-translational, ‘self-cleavage’ site—all regulated by SFHp (Figure 4A). The T2A sequence was derived from \textit{Thosea asigna} virus and shown to have high cleavage efficiency allowing for expression of bicistronic
sequence from a single promoter [43]. As expected, we observed cell-wide Venus fluorescence 24 h after addition of DMOG (Figure 4C). Similarly, the stable HEK293 cells called 'receiver' cells were created by lentiviral infection that expressed Ceru under the regulation of a promoter containing NF-kB response elements derived from the commonly used commercial NF-kB promoter from plasmid pGL4.32 (Promega). This promoter was not optimized to be synthesis-friendly. As expected, receiver cells express Ceru throughout the cell 24 h after induction by addition of 10 ng/mL of active TNFα (Figure S1). When the sender and receiver cell lines were co-incubated together and then induced by addition of DMOG for 24 h, the different cell lines fluoresced Venus and Ceru, respectively (Figure 4C). This sense-response system demonstrates the use of SFHp for inducible intercellular communication with other engineered cell lines. Potentially in cell-based therapies, it allows us to pair the sender cells with a variety of different universal receiver cells responding to sender cell’s TNFα signal. These therapeutic receiver cell lines can likewise be paired with different universal sender cell lines that secrete TNFα under the regulation of other inducible promoters that respond to different stimulus or environmental conditions. Through this kind of rewiring of intercellular signalling, fewer specific cell lines are need to be engineered to have a variety of re-configurable effects. For instance, with a sender cell that drives TNFα expression under SFHp and with a library of receiver cells that drive the TNFα-inducible expression of target genes such as lysozyme (for bactericide), or cathepsin G (for bactericide) or CaRQ-based circuit (for directed migration), it is possible to re-configure the hypoxia-inducible expression of any combination of target genes to test treatment schemas using intercellular signalling. As the library of sender cells expands, the target gene expression can be rewired via intercellular signalling to other inducible stimuli beyond hypoxia.

4 | CONCLUDING REMARKS

We engineered a synthesis-friendly promoter named SFHp that constrains gene expression to hypoxic conditions when stably integrated into HEK293 cells. To do so, we arranged hypoxia responsive elements upstream of a minimal CMV core promoter and checked for repeating sequences and suitable GC content. These two features are common culprits that complicate the synthesis of engineered sequences and subject them to higher prices when commercially synthesized. Furthermore, the lack of these
repeated subsequences in SFHp should make the genetic material more stable and less likely corrupted when integrated into ‘smart’ cell-based therapeutics. We demonstrated the ability of SFHp to express fluorescent proteins (i.e. Ceru and Venus) and engineered protein switches (i.e. CaRQ) upon addition of the DMOG chemical used to activate the HIF-1α transcription factor. Furthermore, we used SFHp-controlled expression of active TNFα, called sender cells, to act as a paracrine signal for hypoxic conditions. This intercellular communication was demonstrated by co-culturing sender cells with receiver cells containing a NFκB-regulated gene circuit. We envision that our synthetic promoter SFHp can be used in engineered therapeutic cells that are administered systemically in order to identify and conditionally express active genes at hypoxic environments within the human body. Hypoxia can act as a therapeutic target for a number of different diseases, including heart disease, cancer and rheumatoid arthritis [15, 16]. As synthetic biology and cellular engineering continues to evolve, it will be important to incorporate systems that exploit the living cell’s ability to detect spatial cues and regulate expression accordingly. The development of our SFHp should allow for the stable integration of genetic material into cell-based therapeutics to detect the hypoxia microenvironment and only then produce therapeutically active genes (e.g. erythropoietin).

ACKNOWLEDGEMENTS
This work was supported by the Canadian Institutes of Health Research [#PJT-156317] and the Natural Science and Engineering Research Council NSERC [#RGPIN-2019-04183].

CONFLICT OF INTEREST
The authors have declared no conflict of interest.

DATA AVAILABILITY STATEMENT
All data generated or analysed during this study are included in this published article (and its supplementary information files).

ORCID
Kevin Truong @ https://orcid.org/0000-0002-9520-2144

REFERENCES
1. Thibodeaux, S. R., Milone, M. C., Immunotherapy using chimeric antigen receptor-engineered T cells: a novel cellular therapy with important implications for the clinical laboratory. Clin. Chem. 2019, 65, 519–529.
2. Muldoon, J. J., Donahue, P. S., Dolberg, T. B., Leonard, J. N., Building with intent: technologies and principles for engineering mammalian cell-based therapies to sense and respond. Curr. Opin. Biomed. Eng. 2017, 4, 127–133.
3. White, M., Whittaker, R., Gándara, C., Stoll, E. A., A guide to approaching regulatory considerations for lentiviral-mediated gene therapies. Hum. Gene Ther. Methods 2017, 28, 163–176.
4. Kallunki, T., Barisic, M., Jäättelä, M., Liu, B., How to choose the right inducible gene expression system for mammalian studies? Cells 2019, 8, 796.
5. Wysocka, A., Green fluorescent protein as a marker for monitoring activity of stress-inducible hsp70 rat gene promoter. Mol. Cell. Biochem. 2000, 215, 153–156.
6. Ning, X., Wang, Y., Yan, W., Li, G., et al. Chitin synthesis inhibitors promote liver cancer cell metastasis via interfering with hypoxia-inducible factor 1alpha. Chemosphere 2018, 206, 231–237.
7. Bruhat, A., Jousse, C., Carraro, V., Reimold, A. M., et al. Amino acids control mammalian gene transcription: activating transcription factor 2 is essential for the amino acid responsiveness of the CHOP promoter. Mol. Cell. Biol. 2000, 20, 7192–7204.
8. Chang, S. H., Mori, D., Kobayashi, H., Mori, Y., et al. Excessive mechanical loading promotes osteoarthritis through the gremlin-1-NF-kappaB pathway. Nat. Commun. 2019, 10, 1442.
9. Semenza, G. L., HIF-1 and human disease: one highly involved factor. Genes Dev. 2000, 14, 1983–1991.
10. Haberle, V., Stark, A., Eukaryotic core promoters and the functional basis of transcription initiation. Nat. Rev. Mol. Cell Biol. 2018, 19, 621–637.
11. Juven-Gershon, T., Kadonaga, J. T., Regulation of gene expression via the core promoter and the basal transcriptional machinery. Dev. Biol. 2010, 339, 225–229.
12. Saxena, P., Bojar, D., Pussenegger, M., Design of synthetic promoters for gene circuits in mammalian cells. Methods Mol. Biol. 2017, 1651, 263–273.
13. Semenza, G. L., Nejfelt, M. K., Chi, S. M., Antonarakis, S. E., Hypoxia-inducible nuclear factors bind to an enhancer element located 3’ to the human erythropoietin gene. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 5680–5684.
14. Wang, G. L., Jiang, B. H., Rue, E. A., Semenza, G. L., Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 5510–5514.
15. Rhim, T., Lee, D. Y., Lee, M., Hypoxia as a target for tissue specific gene therapy. J. Control. Release 2013, 172, 484–494.
16. Biddlestone, J., Bandarra, D., Rocha, S., The role of hypoxia in inflammatory disease (review). Int. J. Mol. Med. 2015, 35, 859–869.
17. Jelkmann, W., Control of erythropoietin gene expression and its use in medicine. Methods Enzymol. 2007, 435, 435–494.
18. Arany, Z., Foo, S.-Y., Ma, Y., Ruas, J. L., et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008, 451, 1008–1012.
19. Lienert, F., Lohmueller, J. J., Garg, A., Silver, P. A., Synthetic biology in mammalian cells: next generation research tools and therapeutics. Nat. Rev. Mol. Cell Biol. 2014, 15, 95–107.
20. Emerling, B. M., Weinberg, F., Liu, J.-L., Mak, T. W., et al. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3α (FOXO3a). Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 2622–2627.
synthesis, and decreases breast cancer metastasis. Mol. Carcinog. 2017, 56, 2317–2331.

22. Wedgwood, S., Lakshminrusimha, S., Schumacker, P. T., Steinhorn, R. H., Hypoxia inducible factor signaling and experimental persistent pulmonary hypertension of the newborn. Front. Pharmacol. 2015, 6, 47.

23. Gibson, D. G., Young, L., Chuang, R.-Y., Venter, J. C., et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 2009, 6, 343–345.

24. Bzymek, M., Lovett, S. T., Instability of repetitive DNA sequences: the role of replication in multiple mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 8319–8325.

25. Tasan, I., Sustackova, G., Zhang, L., Kim, J., et al. CRISPR/Cas9-mediated knock-in of an optimized TetO repeat for live cell imaging of endogenous loci. Nucleic. Acids. Res. 2018, 46, e100.

26. Lam, C. K. C., Truong, K., Engineering a synthesis-friendly constitutive promoter for mammalian cell expression. ACS Synth. Biol. 2020, 9, 2625–2631.

27. Naz, S., Fatima, A., Amplification of GC-rich DNA for high-throughput family-based genetic studies. Mol. Biotechnol. 2013, 53, 345–350.

28. Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399, 271–275.

29. Ivan, M., Kondo, K., Yang, H., Kim, W., et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001, 292, 464–468.

30. Jaakkola, P., Mole, D. R., Tian, Y.-M, Wilson, M. I., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292, 468–472.

31. Mosabbir, A. A., Truong, K., Genomic integration occurs in the packaging cell via unexported lentiviral precursors. Biotechnol. Lett. 2016, 38, 1715–1721.

32. Tanimoto, K., Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000, 19, 4298–4309.

33. Post, D., Van Meir, E., Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther. 2001, 8, 1801-1807.

34. Lin, Y.-C., Boone, M., Meuris, L., Lemmens, I., et al. Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nat. Commun. 2014, 5, 4767.

35. Cui, X. Y., Tinholt, M., Stavik, B., Dahm, A. E. A., et al. Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer. J. Thromb. Haemost. 2016, 14, 387–396.

36. Lee, M., Lee, E. S., Kim, Y. S., Choi, B. H., et al. Ischemic injury-specific gene expression in the rat spinal cord injury model using hypoxia-inducible system. Spine (Phila Pa 1976) 2005, 30, 2729–2734.

37. Wu, Y., Tang, D., Liu, N., Xiong, W., et al. Reciprocal regulation between the circadian clock and hypoxia signaling at the genome level in mammals. Cell Metab. 2017, 25, 73–85.

38. Ziello, J. E., Jovin, I. S., Huang, Y., Hypoxia-inducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J. Biol. Med. 2007, 80, 51–60.

39. Mills, E., Truong, K., Ca2+-mediated synthetic biosystems offer protein design versatility, signal specificity, and pathway rewiring. Cell Chem. Biol. 2011, 18, 1611–1619.

40. Inoue, T., Heo, W. D., Grimley, J. S., Wandless, T. J., et al. An inducible translocation strategy to rapidly activate and inhibit small GTPase signaling pathways. Nat. Methods 2005, 2, 415–418.

41. Kovár-Ová, M., Tolar, P., Arudchandran, R., Dráberová, L., et al. Structure-function analysis of Lyn kinase association with lipid rafts and initiation of early signaling events after Fcepsilon receptor I aggregation. Mol. Cell. Biol. 2001, 21, 8318–8328.

42. Schaffer, K., Taylor, C. T., The impact of hypoxia on bacterial infection. FEBS J. 2015, 282, 2260–2266.

43. Donnelly, M. L. L., Hughes, L. E., Luke, G., Mendoza, H., et al. The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ’2A-like’ sequences. J. Gen. Virol. 2001, 82, 1027–1041.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Lam, C. K. C., Truong, K., Design of a synthesis-friendly hypoxia-responsive promoter for cell-based therapeutics. Eng. Life Sci. 2021, 21, 848–856. https://doi.org/10.1002/elsc.202100045